Today the immunotherapy and related data flooding out of the annual meeting of the San Antonio Breast Cancer Symposium (SABCS) is pretty exciting!
Data was presented on a number of drugs including pembrolizumab, avelumab and atezolizumab, which put together with some recent publications, highlights some potentially exciting opportunities in this fast moving space.
Here, we explore the potential for checkpoint therapy combinations in TNBC, HER2 and even the ER+ subsets. There’s a lot of new findings to take in and contemplate here.
Subscribers can log-in or you can sign up in the box below to learn more about this emerging area in cancer immunotherapy new product development.